Daily Stock Analysis, NKTR, Nektar Therapeutics, priceseries

Nektar Therapeutics. Daily Stock Analysis
Stock Information
Open
10.35
Close
10.12
High
10.52
Low
9.91
Previous Close
10.50
Daily Price Gain
-0.38
YTD High
14.06
YTD High Date
Jan 3, 2022
YTD Low
9.31
YTD Low Date
Feb 24, 2022
YTD Price Change
-3.54
YTD Gain
-25.92%
52 Week High
23.50
52 Week High Date
Mar 18, 2021
52 Week Low
9.31
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-11.10
52 Week Gain
-52.31%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 7. 2017
14.26
Apr 4. 2017
22.45
20 Trading Days
57.46%
Link
LONG
Aug 28. 2017
19.11
Sep 19. 2017
21.84
15 Trading Days
14.30%
Link
LONG
Nov 6. 2017
24.28
Dec 6. 2017
49.28
21 Trading Days
102.98%
Link
LONG
Jan 18. 2018
70.16
Feb 6. 2018
79.80
13 Trading Days
13.74%
Link
LONG
Aug 20. 2018
60.60
Sep 6. 2018
64.62
12 Trading Days
6.63%
Link
LONG
Jan 4. 2019
33.96
Jan 24. 2019
43.26
13 Trading Days
27.40%
Link
LONG
Sep 9. 2019
17.86
Sep 24. 2019
19.38
11 Trading Days
8.53%
Link
LONG
May 7. 2020
19.88
May 28. 2020
22.42
14 Trading Days
12.77%
Link
LONG
Jan 25. 2021
17.74
Feb 22. 2021
22.70
19 Trading Days
27.98%
Link
LONG
Aug 27. 2021
14.95
Oct 5. 2021
17.67
26 Trading Days
18.18%
Link
LONG
Dec 6. 2021
11.86
Dec 29. 2021
14.30
16 Trading Days
20.54%
Link
Company Information
Stock Symbol
NKTR
Exchange
NasdaqGS
Company URL
http://www.nektar.com
Company Phone
4154825300
CEO
Howard W. Robin
Headquarters
California
Business Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA 94158
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000906709
About

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products includes of drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. It provides small molecule drugs, peptides and other potential biologic drug candidates. It's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. The company was founded in 1990 and is headquartered in San Francisco, CA.

Description

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358 to treat autoimmune diseases. The company's drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat refractory solid tumor cancers, which has completed Phase I clinical trial. In addition, it holds license, manufacturing, and supply agreements with Ophthotech Corporation for Fovista; and UCB Pharma for dapirolizumab pegol. Further, the company holds a range of license, manufacturing, and supply agreements with other biotechnology and pharmaceutical companies, including Amgen Inc.; Allergan, Inc.; Merck & Co., Inc.; Pfizer, Inc.; and F. Hoffmann-La Roche Ltd (Roche). Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.